The Hematology Research Training Program at the University of Washington is designed to provide intensive post-doctoral research training in investigative hematology. The program emphasizes cell and molecular biology, with particular strengths in: stem cells and hematopoiesis, cell and gene therapy, platelets and hemostasis, vascular biology, hematologic malignancies, cancer biology, and hematopoietic cell transplantation. Program faculty includes established investigators with strong independent research programs from both basic science and clinical departments at the University of Washington, Fred Hutchinson Cancer Research Center, and nearby affiliated institutions. The goal of the Training Program is to develop the research, presentation, and fund-raising skills that trainees will need to establish independent research careers, and to train future leaders in the field of research hematology. Trainees have MD, MD/PhD or PhD degrees. Many have completed clinical training in hematology, but others are basic researchers wishing to work in the field. Trainees are chosen through an application process and interactions with program faculty. They obtain laboratory experience by working with a mentor, and are assisted in laboratory techniques, publishing papers, presentation skills, and acquiring independent grant support. Trainees typically receive 2 years of funding from the Program, but often continue their training longer under separate funding mechanisms. Training progress is monitored by the faculty mentor, a separate faculty advisor, the Program Directors, and the Division of Hematology faculty through regular research presentations and meetings with each trainee. The main strengths of the Program include: diverse research opportunities, a qualified senior faculty, and a long track record, spanning over four decades of graduates obtaining junior faculty positions and becoming independent and distinguished investigators.

Agency
National Institute of Health (NIH)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL007093-40
Application #
8689132
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Chang, Henry
Project Start
Project End
Budget Start
Budget End
Support Year
40
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98195
Fox, Edward J; Salk, Jesse J; Loeb, Lawrence A (2016) Exploring the implications of distinct mutational signatures and mutation rates in aging and cancer. Genome Med 8:30
Stanaway, Jeffrey D; Flaxman, Abraham D; Naghavi, Mohsen et al. (2016) The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388:1081-8
Samuelson, Bethany T; Cuker, Adam (2016) Measurement and reversal of the direct oral anticoagulants. Blood Rev :
Graf, Solomon A; Gopal, Ajay K (2016) Idelalisib for the treatment of non-Hodgkin lymphoma. Expert Opin Pharmacother 17:265-74
Global Burden of Disease Pediatrics Collaboration; Kyu, Hmwe H; Pinho, Christine et al. (2016) Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013: Findings From the Global Burden of Disease 2013 Study. JAMA Pediatr 170:267-87
Zhou, Y; Othus, M; Araki, D et al. (2016) Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia 30:1456-64
Buckley, Sarah A; Lee, Stephanie J; Walter, Roland B (2016) Measuring quality of life in acute myeloid leukemia: limitations and future directions. Expert Rev Hematol 9:821-3
Vaughn, J E; Anwer, F; Deeg, H J (2016) Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom? Vox Sang 110:5-11
Cowan, Andrew J; Stevenson, Philip A; Cassaday, Ryan D et al. (2016) Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. Biol Blood Marrow Transplant 22:380-5
Maxson, Julia E; Luty, Samuel B; MacManiman, Jason D et al. (2016) The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I. Clin Cancer Res 22:757-64

Showing the most recent 10 out of 78 publications